1
|
Abdelrazek NA, Saleh SE, Raafat MM, Ali AE, Aboulwafa MM. Production of highly cytotoxic and low immunogenic L-asparaginase from Stenotrophomonas maltophilia EMCC2297. AMB Express 2024; 14:51. [PMID: 38704453 PMCID: PMC11069494 DOI: 10.1186/s13568-024-01700-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2024] [Accepted: 04/09/2024] [Indexed: 05/06/2024] Open
Abstract
L-asparaginase is an important therapeutic enzyme that is frequently utilized in the chemotherapy regimens of adults as well as pediatric patients with acute lymphoblastic leukemia. However, a high rate of hypersensitivity with prolonged use has limited its utilization. Stenotrophomonas maltophilia (S. maltophilia) EMCC2297 isolate was reported as a novel and promising source for L- asparaginase. The present study aimed at the production, purification, and characterization of L- asparaginase from S. maltophilia EMCC2297 isolate. The microbial production of L-asparaginase by the test isolate could be increased by pre-exposure to chloramphenicol at 200 µg/ml concentration. S. maltophilia EMCC2297 L-asparaginase could be purified to homogeneity by ammonium sulphate precipitation and the purified form obtained by gel exclusion chromatography showed total activity of 96.4375 IU/ml and specific activity of 36.251 IU/mg protein. SDS-PAGE analysis revealed that the purified form of the enzyme is separated at an apparent molecular weight of 17 KDa. Michaelis-Menten constant analysis showed a Km value of 4.16 × 10- 2 M with L-asparagine as substrate and Vmax of 10.67 IU/ml. The antitumor activity of the purified enzyme was evaluated on different cell lines and revealed low IC50 of 2.2 IU/ml and 2.83 IU/ml for Hepatocellular cancer cell line (HepG-2), human leukemia cancer cell line (K-562), respectively whereas no cytotoxic effect could be detected on normal human lung fibroblast cells (MRC-5). However, mice treated with native L-asparaginase showed lower IgG titre compared to commercial L-asparaginase. This study highlights the promising characteristics of this enzyme making it a valuable candidate for further research and development to be an adduct in cancer chemotherapy.
Collapse
Affiliation(s)
- Nada A Abdelrazek
- Department of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, Al Khalifa Al Maamoun St., Abbassia, Cairo, 11517, Egypt
| | - Sarra E Saleh
- Department of Microbiology and immunology, Faculty of Pharmacy, Future University in Egypt, Cairo, Egypt
| | - Marwa M Raafat
- Department of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, Al Khalifa Al Maamoun St., Abbassia, Cairo, 11517, Egypt
| | - Amal E Ali
- Department of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, Al Khalifa Al Maamoun St., Abbassia, Cairo, 11517, Egypt
| | - Mohammad M Aboulwafa
- Department of Microbiology and immunology, Faculty of Pharmacy, Future University in Egypt, Cairo, Egypt.
- Department of Microbiology and Immunology, Faculty of Pharmacy, King Salman International University, South Sinai, Ras-Sudr, Egypt.
| |
Collapse
|
2
|
Agbayani G, Akache B, Renner TM, Tran A, Stuible M, Dudani R, Harrison BA, Duque D, Bavananthasivam J, Deschatelets L, Hemraz UD, Régnier S, Durocher Y, McCluskie MJ. Intranasal administration of unadjuvanted SARS-CoV-2 spike antigen boosts antigen-specific immune responses induced by parenteral protein subunit vaccine prime in mice and hamsters. Eur J Immunol 2024:e2350620. [PMID: 38561974 DOI: 10.1002/eji.202350620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Revised: 03/14/2024] [Accepted: 03/18/2024] [Indexed: 04/04/2024]
Abstract
With the continued transmission of SARS-CoV-2 across widely vaccinated populations, it remains important to develop new vaccines and vaccination strategies capable of providing protective immunity and limiting the spread of disease. Heterologous prime-boost vaccination based on the selection of different vaccine formulations and administration routes for priming and booster doses presents a promising strategy for inducing broader immune responses in key systemic and respiratory mucosal compartments. Intranasal vaccination can induce mucosal immune responses at the site of SARS-CoV-2 infection; however, the lack of clinically approved mucosal adjuvants makes it difficult to induce robust immune responses with protein subunit vaccines. Herein, we evaluated the immunogenicity of heterologous prime-boost regimens in mice and hamsters based on a parenteral vaccination of the antigen in combination with sulfated lactosylarchaeol (SLA) archaeosomes, a liposome adjuvant comprised of a single semisynthetic archaeal lipid, followed by an intranasally administered unadjuvanted SARS-CoV-2 spike antigen. Intranasal administration of unadjuvanted spike to mice and hamsters increased serum spike-specific IgG titers and spike-neutralizing activity compared with nonboosted animals. Spike-specific IgA responses were also detected in the bronchoalveolar lavage fluid in the lungs of mice that received an intranasal boost. In hamsters, the intranasal boost showed high efficacy against SARS-CoV-2 infection by protecting from body weight loss and reducing viral titers in the lungs and nasal turbinate. Overall, our heterologous intramuscular prime-intranasal boost with SLA-adjuvanted and unadjuvanted spike, respectively, demonstrated the potential of protein subunit formulations to promote antigen-specific systemic and mucosal immune responses.
Collapse
Affiliation(s)
- Gerard Agbayani
- Human Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada
| | - Bassel Akache
- Human Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada
| | - Tyler M Renner
- Human Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada
| | - Anh Tran
- Human Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada
| | - Matthew Stuible
- Human Health Therapeutics Research Centre, National Research Council Canada, Montreal, Quebec, Canada
| | - Renu Dudani
- Human Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada
| | - Blair A Harrison
- Human Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada
| | - Diana Duque
- Human Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada
| | - Jegarubee Bavananthasivam
- Human Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada
| | - Lise Deschatelets
- Human Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada
| | - Usha D Hemraz
- Human Health Therapeutics Research Centre, National Research Council Canada, Montreal, Quebec, Canada
| | - Sophie Régnier
- Aquatic and Crop Resource Development Research Centre, National Research Council Canada, Montreal, Quebec, Canada
| | - Yves Durocher
- Human Health Therapeutics Research Centre, National Research Council Canada, Montreal, Quebec, Canada
| | - Michael J McCluskie
- Human Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada
| |
Collapse
|
3
|
Akache B, Read AJ, Dudani R, Harrison BA, Williams D, Deschatelets L, Jia Y, Chandan V, Stark FC, Agbayani G, Makinen SR, Hemraz UD, Lam E, Régnier S, Zou W, Kirkland PD, McCluskie MJ. Sulfated Lactosyl Archaeol Archaeosome-Adjuvanted Vaccine Formulations Targeting Rabbit Hemorrhagic Disease Virus Are Immunogenic and Efficacious. Vaccines (Basel) 2023; 11:1043. [PMID: 37376432 DOI: 10.3390/vaccines11061043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Revised: 05/24/2023] [Accepted: 05/27/2023] [Indexed: 06/29/2023] Open
Abstract
Vaccines play an important role in maintaining human and animal health worldwide. There is continued demand for effective and safe adjuvants capable of enhancing antigen-specific responses to a target pathogen. Rabbit hemorrhagic disease virus (RHDV) is a highly contagious calicivirus that often induces high mortality rates in rabbits. Herein, we evaluated the activity of an experimental sulfated lactosyl archaeol (SLA) archaeosome adjuvant when incorporated in subunit vaccine formulations targeting RHDV. The subunit antigens consisted of RHDV-CRM197 peptide conjugates or recombinant RHDV2 VP60. SLA was able to enhance antigen-specific antibody titers and cellular responses in mice and rabbits. Three weeks following immunization, antigen-specific antibody levels in rabbits vaccinated with RHDV2 VP60 + SLA were significantly higher than those immunized with antigen alone, with geomean titers of 7393 vs. 117. In addition, the SLA-adjuvanted VP60-based formulations were highly efficacious in a rabbit RHDV2 challenge model with up to 87.5% animals surviving the viral challenge. These findings demonstrate the potential utility of SLA adjuvants in veterinary applications and highlight its activity in different types of mammalian species.
Collapse
Affiliation(s)
- Bassel Akache
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Andrew J Read
- Virology Laboratory, Elizabeth Macarthur Agricultural Institute, NSW Department of Primary Industries, Menangle, NSW 2567, Australia
| | - Renu Dudani
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Blair A Harrison
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Dean Williams
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Lise Deschatelets
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Yimei Jia
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Vandana Chandan
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Felicity C Stark
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Gerard Agbayani
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Shawn R Makinen
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Usha D Hemraz
- National Research Council Canada, Aquatic and Crop Resource Development, Montreal, QC H4P 2R2, Canada
| | - Edmond Lam
- National Research Council Canada, Aquatic and Crop Resource Development, Montreal, QC H4P 2R2, Canada
| | - Sophie Régnier
- National Research Council Canada, Aquatic and Crop Resource Development, Montreal, QC H4P 2R2, Canada
| | - Wei Zou
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Peter D Kirkland
- Virology Laboratory, Elizabeth Macarthur Agricultural Institute, NSW Department of Primary Industries, Menangle, NSW 2567, Australia
| | - Michael J McCluskie
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| |
Collapse
|
4
|
Romero EL, Morilla MJ. Ether lipids from archaeas in nano-drug delivery and vaccination. Int J Pharm 2023; 634:122632. [PMID: 36690132 DOI: 10.1016/j.ijpharm.2023.122632] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2022] [Revised: 12/26/2022] [Accepted: 01/17/2023] [Indexed: 01/22/2023]
Abstract
Archaea are microorganisms more closely related to eukaryotes than bacteria. Almost 50 years after being defined as a new domain of life on earth, new species continue to be discovered and their phylogeny organized. The study of the relationship between their genetics and metabolism and some of their extreme habitats has even positioned them as a model of extraterrestrial life forms. Archaea, however, are deeply connected to the life of our planet: they can be found in arid, acidic, warm areas; on most of the earth's surface, which is cold (below 5 °C), playing a prominent role in the cycles of organic materials on a global scale and they are even part of our microbiota. The constituent materials of these microorganisms differ radically from those produced by eukaryotes and bacteria, and the nanoparticles that can be manufactured using their ether lipids as building blocks exhibit unique properties that are of interest in nanomedicine. Here, we present for the first time a complete overview of the pre-clinical applications of nanomedicines based on ether archaea lipids, focused on drug delivery and adjuvancy over the last 25 years, along with a discussion on their pros, cons and their future industrial implementation.
Collapse
Affiliation(s)
- Eder Lilia Romero
- Nanomedicines Research and Development Centre (NARD), Science and Technology Department, National University of Quilmes, Roque Sáenz Peña 352, Bernal, Buenos Aires, Argentina.
| | - Maria Jose Morilla
- Nanomedicines Research and Development Centre (NARD), Science and Technology Department, National University of Quilmes, Roque Sáenz Peña 352, Bernal, Buenos Aires, Argentina
| |
Collapse
|
5
|
Batty CJ, Amouzougan EA, A Carlock M, Ross TM, Bachelder EM, Ainslie KM. Sustained delivery of CpG oligodeoxynucleotide by acetalated dextran microparticles augments effector response to Computationally Optimized Broadly Reactive Antigen (COBRA) influenza hemagglutinin. Int J Pharm 2023; 630:122429. [PMID: 36436743 PMCID: PMC9789738 DOI: 10.1016/j.ijpharm.2022.122429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2022] [Revised: 11/16/2022] [Accepted: 11/19/2022] [Indexed: 11/27/2022]
Abstract
A subunit or protein-based influenza vaccine can be a safer alternative to live attenuated vaccine (Flumist) and require fewer boosts than an inactivated vaccine (e.g. Fluzone). However, to form an effective subunit vaccine, an adjuvant is often needed. In this work we used electrospray to encapsulate the hydrophilic adjuvant CpG into microparticles made from the hydrophobic biodegradable polymer acetalated dextran. To understand the rate of particle degradation on CpG release, polymer that was slow (21 h at phagosomal pH 5) and fast (0.25 h at pH 5) degrading was used to encapsulate the adjuvant. The slow-degrading particles exhibited the greatest degree of innate immune stimulation of antigen-presenting cells in vitro. In mice, the broadly acting Computationally Optimized Broadly Reactive Antigen (COBRA) Y2 influenza hemagglutinin (HA) antigen was used with CpG particles, soluble CpG, or MF-59 like adjuvant Addavax. Particles and soluble CpG elicited similar induction of anti-HA antibodies and protection against lethal influenza challenge, but the sustained release particles elicited the highest levels antibody effector functions. These results demonstrate a suitable method for encapsulation of CpG oligonucleotide in a hydrophobic particle matrix, and suggest that sustained release of CpG from Ace-DEX microparticles could potentially be used to induce potent antibody effector functions.
Collapse
Affiliation(s)
- Cole J Batty
- Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | - Eva A Amouzougan
- Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | - Michael A Carlock
- Center for Vaccines and Immunology, University of Georgia, Athens, GA, USA
| | - Ted M Ross
- Center for Vaccines and Immunology, University of Georgia, Athens, GA, USA; Department of Infectious Diseases, University of Georgia, Athens, GA, USA
| | - Eric M Bachelder
- Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | - Kristy M Ainslie
- Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, NC, USA.
| |
Collapse
|
6
|
Jia Y, Agbayani G, Chandan V, Iqbal U, Dudani R, Qian H, Jakubek Z, Chan K, Harrison B, Deschatelets L, Akache B, McCluskie MJ. Evaluation of Adjuvant Activity and Bio-Distribution of Archaeosomes Prepared Using Microfluidic Technology. Pharmaceutics 2022; 14:2291. [PMID: 36365110 PMCID: PMC9697222 DOI: 10.3390/pharmaceutics14112291] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Revised: 10/18/2022] [Accepted: 10/20/2022] [Indexed: 09/24/2023] Open
Abstract
Archaeosomes, composed of sulfated lactosyl archaeol (SLA) glycolipids, have been proven to be an effective vaccine adjuvant in multiple preclinical models of infectious disease or cancer. They have classically been prepared using a thin-film hydration method with an average particle size of 100-200 nm. In this study, we developed methods to generate SLA archaeosomes at different sizes, i.e., 30 nm and 100 nm, via microfluidic mixing technology and evaluated their physicochemical characteristics, as well as adjuvant activity and in vivo biodistribution in mice. Archaeosomes, prepared using thin-film and microfluidic mixing techniques, had similar nanostructures and physicochemical characteristics, with both appearing stable during the course of this study when stored at 4 °C or 37 °C. They also demonstrated similar adjuvant activity when admixed with ovalbumin antigen and used to immunize mice, generating equivalent antigen-specific immune responses. Archaeosomes, labeled with CellVueTM NIR815, had an equivalent biodistribution with both sizes, namely the highest signal at the injection site at 24 h post injection, followed by liver, spleen and inguinal lymph node. The presence of SLA archaeosomes of either size helped to retain OVA antigen (OVA-Cy5.5) longer at the injection site than unadjuvanted OVA. Overall, archaeosomes of two sizes (30 nm and 100 nm) prepared using microfluidic mixing maintained similar physicochemical properties, adjuvant activity and biodistribution of antigen, in comparison to those compared by the conventional thin film hydration method. This suggests that microfluidics based approaches could be applied to generate consistently sized archaeosomes for use as a vaccine adjuvant.
Collapse
Affiliation(s)
- Yimei Jia
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A0R6, Canada
| | - Gerard Agbayani
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A0R6, Canada
| | - Vandana Chandan
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A0R6, Canada
| | - Umar Iqbal
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A0R6, Canada
| | - Renu Dudani
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A0R6, Canada
| | - Hui Qian
- Nanotechnology Research Centre, National Research Council Canada, Edmonton, AB T6G2M9, Canada
| | - Zygmunt Jakubek
- Metrology Research Centre, National Research Council Canada, Ottawa, ON K1A0R6, Canada
| | - Kenneth Chan
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A0R6, Canada
| | - Blair Harrison
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A0R6, Canada
| | - Lise Deschatelets
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A0R6, Canada
| | - Bassel Akache
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A0R6, Canada
| | - Michael J. McCluskie
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A0R6, Canada
| |
Collapse
|
7
|
Vesicular and Planar Membranes of Archaea Lipids: Unusual Physical Properties and Biomedical Applications. Int J Mol Sci 2022; 23:ijms23147616. [PMID: 35886964 PMCID: PMC9319432 DOI: 10.3390/ijms23147616] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Revised: 06/27/2022] [Accepted: 06/27/2022] [Indexed: 12/12/2022] Open
Abstract
Liposomes and planar membranes made of archaea or archaea-like lipids exhibit many unusual physical properties compared to model membranes composed of conventional diester lipids. Here, we review several recent findings in this research area, which include (1) thermosensitive archaeosomes with the capability to drastically change the membrane surface charge, (2) MthK channel's capability to insert into tightly packed tetraether black lipid membranes and exhibit channel activity with surprisingly high calcium sensitivity, and (3) the intercalation of apolar squalane into the midplane space of diether bilayers to impede proton permeation. We also review the usage of tetraether archaeosomes as nanocarriers of therapeutics and vaccine adjuvants, as well as the biomedical applications of planar archaea lipid membranes. The discussion on archaeosomal therapeutics is focused on partially purified tetraether lipid fractions such as the polar lipid fraction E (PLFE) and glyceryl caldityl tetraether (GCTE), which are the main components of PLFE with the sugar and phosphate removed.
Collapse
|
8
|
Régnier S, Lam E, Vasquez V, Martinez-Farina CF, Stark FC, Agbayani G, Deschatelets L, Dudani R, Harrison BA, Akache B, McCluskie MJ, Hemraz UD. Effect of Chiral Purity on Adjuvanticity of Archaeol-Based Glycolipids. J Med Chem 2022; 65:8332-8344. [PMID: 35658102 DOI: 10.1021/acs.jmedchem.2c00072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Archaeosomes composed of sulfated lactosyl archaeol (SLA) glycolipids from stereoisomerically pure archaeol (1) are vaccine adjuvants that can boost immunogenicity and vaccine efficacy in preclinical models. Herein, we report a new synthesis of 2,3-bis((3,7,11,15-tetramethylhexadecyl)oxy) propan-1-ol (3) by treating (±)-3-benzyloxy-1,2-propanediol with a mesylated phytol derivative through a double nucleophilic substitution reaction, followed by reductive debenzylation. Three SLA archaeosomes from archaeols of different chiral purities were prepared, and the effect of stereochemistry on their adjuvanticity toward ovalbumin was investigated. It was found that all SLA archaeosomes induced strong humoral and cell-mediated antigen-specific immune responses following immunization of C57BL/6NCrl mice, with no significant differences, irrespective of the chiral purities. The responses were comparable or better than those obtained using mimetics of approved adjuvants. The performance of SLA archaeosomes during immunization and their lack of dependence on the stereochemistry of archaeol points toward a promising, safe, scalable, and economically viable vaccine adjuvant system.
Collapse
Affiliation(s)
- Sophie Régnier
- Aquatic and Crop Resource Development, National Research Council of Canada, 6100 Royalmount Avenue, Montreal, Quebec H4P 2R2, Canada
| | - Edmond Lam
- Aquatic and Crop Resource Development, National Research Council of Canada, 6100 Royalmount Avenue, Montreal, Quebec H4P 2R2, Canada
| | - Vinicio Vasquez
- Aquatic and Crop Resource Development, National Research Council of Canada, 6100 Royalmount Avenue, Montreal, Quebec H4P 2R2, Canada
| | - Camilo F Martinez-Farina
- Aquatic and Crop Resource Development, National Research Council of Canada, 1411 Oxford Street, Halifax, Nova Scotia B3H 3Z1, Canada
| | - Felicity C Stark
- Human Health Therapeutics, National Research Council of Canada, 1200 Montreal Rd, Ottawa, Ontario K1A 0R6, Canada
| | - Gerard Agbayani
- Human Health Therapeutics, National Research Council of Canada, 1200 Montreal Rd, Ottawa, Ontario K1A 0R6, Canada
| | - Lise Deschatelets
- Human Health Therapeutics, National Research Council of Canada, 1200 Montreal Rd, Ottawa, Ontario K1A 0R6, Canada
| | - Renu Dudani
- Human Health Therapeutics, National Research Council of Canada, 1200 Montreal Rd, Ottawa, Ontario K1A 0R6, Canada
| | - Blair A Harrison
- Human Health Therapeutics, National Research Council of Canada, 1200 Montreal Rd, Ottawa, Ontario K1A 0R6, Canada
| | - Bassel Akache
- Human Health Therapeutics, National Research Council of Canada, 1200 Montreal Rd, Ottawa, Ontario K1A 0R6, Canada
| | - Michael J McCluskie
- Human Health Therapeutics, National Research Council of Canada, 1200 Montreal Rd, Ottawa, Ontario K1A 0R6, Canada
| | - Usha D Hemraz
- Aquatic and Crop Resource Development, National Research Council of Canada, 6100 Royalmount Avenue, Montreal, Quebec H4P 2R2, Canada
| |
Collapse
|
9
|
Akache B, Stark FC, Agbayani G, Renner TM, McCluskie MJ. Adjuvants: Engineering Protective Immune Responses in Human and Veterinary Vaccines. Methods Mol Biol 2022; 2412:179-231. [PMID: 34918246 DOI: 10.1007/978-1-0716-1892-9_9] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Adjuvants are key components of many vaccines, used to enhance the level and breadth of the immune response to a target antigen, thereby enhancing protection from the associated disease. In recent years, advances in our understanding of the innate and adaptive immune systems have allowed for the development of a number of novel adjuvants with differing mechanisms of action. Herein, we review adjuvants currently approved for human and veterinary use, describing their use and proposed mechanisms of action. In addition, we will discuss additional promising adjuvants currently undergoing preclinical and/or clinical testing.
Collapse
Affiliation(s)
- Bassel Akache
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON, Canada
| | - Felicity C Stark
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON, Canada
| | - Gerard Agbayani
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON, Canada
| | - Tyler M Renner
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON, Canada
| | - Michael J McCluskie
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON, Canada.
| |
Collapse
|
10
|
Akache B, Jia Y, Chandan V, Deschatelets L, McCluskie MJ. Generation of a Liposomal Vaccine Adjuvant Based on Sulfated S-Lactosylarchaeol (SLA) Glycolipids. Methods Mol Biol 2022; 2412:255-267. [PMID: 34918249 DOI: 10.1007/978-1-0716-1892-9_12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Vaccine formulations utilize adjuvants to enhance the level and breadth of the immune response to a target antigen. Liposomes composed of sulfated S-lactosylarchaeol (SLA) glycolipids can induce strong humoral and cell-mediated antigen-specific immune responses to co-administered antigens in mice. This has been demonstrated with a variety of protein antigens, where the protein is either encapsulated within or simply admixed with the archaeal liposomes (archaeosomes). In this process, a dried film of SLA glycolipid is hydrated in water or antigen solution to generate a large multilamellar (ML) liposomal suspension which is then size reduced by sonication to form unilamellar vesicles (UL) with a narrower size distribution. Herein, we describe the generation of liposomes based on the archaeal-based lipid SLA for use as an adjuvant in vaccine formulations.
Collapse
Affiliation(s)
- Bassel Akache
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON, Canada
| | - Yimei Jia
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON, Canada
| | - Vandana Chandan
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON, Canada
| | - Lise Deschatelets
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON, Canada
| | - Michael J McCluskie
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON, Canada.
| |
Collapse
|
11
|
Akache B, Renner TM, Tran A, Deschatelets L, Dudani R, Harrison BA, Duque D, Haukenfrers J, Rossotti MA, Gaudreault F, Hemraz UD, Lam E, Régnier S, Chen W, Gervais C, Stuible M, Krishnan L, Durocher Y, McCluskie MJ. Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant. Sci Rep 2021; 11:21849. [PMID: 34750472 PMCID: PMC8576046 DOI: 10.1038/s41598-021-01363-7] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2021] [Accepted: 10/26/2021] [Indexed: 12/23/2022] Open
Abstract
The huge worldwide demand for vaccines targeting SARS-CoV-2 has necessitated the continued development of novel improved formulations capable of reducing the burden of the COVID-19 pandemic. Herein, we evaluated novel protein subunit vaccine formulations containing a resistin-trimerized spike antigen, SmT1. When combined with sulfated lactosyl archaeol (SLA) archaeosome adjuvant, formulations induced robust antigen-specific humoral and cellular immune responses in mice. Antibodies had strong neutralizing activity, preventing viral spike binding and viral infection. In addition, the formulations were highly efficacious in a hamster challenge model reducing viral load and body weight loss even after a single vaccination. The antigen-specific antibodies generated by our vaccine formulations had stronger neutralizing activity than human convalescent plasma, neutralizing the spike proteins of the B.1.1.7 and B.1.351 variants of concern. As such, our SmT1 antigen along with SLA archaeosome adjuvant comprise a promising platform for the development of efficacious protein subunit vaccine formulations for SARS-CoV-2.
Collapse
Affiliation(s)
- Bassel Akache
- National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada
| | - Tyler M Renner
- National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada
| | - Anh Tran
- National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada
| | - Lise Deschatelets
- National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada
| | - Renu Dudani
- National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada
| | - Blair A Harrison
- National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada
| | - Diana Duque
- National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada
| | - Julie Haukenfrers
- National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada
| | - Martin A Rossotti
- National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada
| | - Francis Gaudreault
- National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada
| | - Usha D Hemraz
- National Research Council Canada, Aquatic and Crop Resource Development, 6100 Avenue Royalmount, Montreal, QC, H4P 2R2, Canada
| | - Edmond Lam
- National Research Council Canada, Aquatic and Crop Resource Development, 6100 Avenue Royalmount, Montreal, QC, H4P 2R2, Canada
| | - Sophie Régnier
- National Research Council Canada, Aquatic and Crop Resource Development, 6100 Avenue Royalmount, Montreal, QC, H4P 2R2, Canada
| | - Wangxue Chen
- National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada
| | - Christian Gervais
- National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada
| | - Matthew Stuible
- National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada
| | - Lakshmi Krishnan
- National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada
| | - Yves Durocher
- National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada
| | - Michael J McCluskie
- National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada.
| |
Collapse
|
12
|
Adamiak N, Krawczyk KT, Locht C, Kowalewicz-Kulbat M. Archaeosomes and Gas Vesicles as Tools for Vaccine Development. Front Immunol 2021; 12:746235. [PMID: 34567012 PMCID: PMC8462270 DOI: 10.3389/fimmu.2021.746235] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2021] [Accepted: 08/27/2021] [Indexed: 12/03/2022] Open
Abstract
Archaea are prokaryotic organisms that were classified as a new domain in 1990. Archaeal cellular components and metabolites have found various applications in the pharmaceutical industry. Some archaeal lipids can be used to produce archaeosomes, a new family of liposomes that exhibit high stability to temperatures, pH and oxidative conditions. Additionally, archaeosomes can be efficient antigen carriers and adjuvants promoting humoral and cellular immune responses. Some archaea produce gas vesicles, which are nanoparticles released by the archaea that increase the buoyancy of the cells and facilitate an upward flotation in water columns. Purified gas vesicles display a great potential for bioengineering, due to their high stability, immunostimulatory properties and uptake across cell membranes. Both archaeosomes and archaeal gas vesicles are attractive tools for the development of novel drug and vaccine carriers to control various diseases. In this review we discuss the current knowledge on production, preparation methods and potential applications of archaeosomes and gas vesicles as carriers for vaccines. We give an overview of the traditional structures of these carriers and their modifications. A comparative analysis of both vaccine delivery systems, including their advantages and limitations of their use, is provided. Gas vesicle- and archaeosome-based vaccines may be powerful next-generation tools for the prevention and treatment of a wide variety of infectious and non-infectious diseases.
Collapse
Affiliation(s)
- Natalia Adamiak
- Department of Immunology and Infectious Biology, Institute of Microbiology, Biotechnology and Immunology, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland
| | - Krzysztof T Krawczyk
- Department of Immunology and Infectious Biology, Institute of Microbiology, Biotechnology and Immunology, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland
| | - Camille Locht
- Department of Immunology and Infectious Biology, Institute of Microbiology, Biotechnology and Immunology, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.,Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France
| | - Magdalena Kowalewicz-Kulbat
- Department of Immunology and Infectious Biology, Institute of Microbiology, Biotechnology and Immunology, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland
| |
Collapse
|
13
|
Durán-Lobato M, López-Estévez AM, Cordeiro AS, Dacoba TG, Crecente-Campo J, Torres D, Alonso MJ. Nanotechnologies for the delivery of biologicals: Historical perspective and current landscape. Adv Drug Deliv Rev 2021; 176:113899. [PMID: 34314784 DOI: 10.1016/j.addr.2021.113899] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2021] [Revised: 07/05/2021] [Accepted: 07/23/2021] [Indexed: 12/12/2022]
Abstract
Biological macromolecule-based therapeutics irrupted in the pharmaceutical scene generating a great hope due to their outstanding specificity and potency. However, given their susceptibility to degradation and limited capacity to overcome biological barriers new delivery technologies had to be developed for them to reach their targets. This review aims at analyzing the historical seminal advances that shaped the development of the protein/peptide delivery field, along with the emerging technologies on the lead of the current landscape. Particularly, focus is made on technologies with a potential for transmucosal systemic delivery of protein/peptide drugs, followed by approaches for the delivery of antigens as new vaccination strategies, and formulations of biological drugs in oncology, with special emphasis on mAbs. Finally, a discussion of the key challenges the field is facing, along with an overview of prospective advances are provided.
Collapse
|
14
|
Akache B, Agbayani G, Stark FC, Jia Y, Dudani R, Harrison BA, Deschatelets L, Chandan V, Lam E, Hemraz UD, Régnier S, Krishnan L, McCluskie MJ. Sulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor Model. Pharmaceutics 2021; 13:pharmaceutics13020257. [PMID: 33673382 PMCID: PMC7918940 DOI: 10.3390/pharmaceutics13020257] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2021] [Revised: 02/08/2021] [Accepted: 02/09/2021] [Indexed: 12/17/2022] Open
Abstract
Cancer remains a leading cause of morbidity and mortality worldwide. While novel treatments have improved survival outcomes for some patients, new treatment modalities/platforms are needed to combat a wider variety of tumor types. Cancer vaccines harness the power of the immune system to generate targeted tumor-specific immune responses. Liposomes composed of glycolipids derived from archaea (i.e., archaeosomes) have been shown to be potent adjuvants, inducing robust, long-lasting humoral and cell-mediated immune responses to a variety of antigens. Herein, we evaluated the ability of archaeosomes composed of sulfated lactosyl archaeol (SLA), a semi-synthetic archaeal glycolipid, to enhance the immunogenicity of a synthetic long peptide-based vaccine formulation containing the dominant CD8+ T cell epitope, SIINFEKL, from the weakly immunogenic model antigen ovalbumin. One advantage of immunizing with long peptides is the ability to include multiple epitopes, for example, the long peptide antigen was also designed to include the immediately adjacent CD4+ epitope, TEWTSSNVMEER. SLA archaeosomes were tested alone or in combination with the toll-like receptor 3 (TLR3) agonist Poly(I:C). Overall, SLA archaeosomes synergized strongly with Poly(I:C) to induce robust antigen-specific CD8+ T cell responses, which were highly functional in an in vivo cytolytic assay. Furthermore, immunization with this vaccine formulation suppressed tumor growth and extended mouse survival in a mouse melanoma tumor model. Overall, the combination of SLA archaeosomes and Poly(I:C) appears to be a promising adjuvant system when used along with long peptide-based antigens targeting cancer.
Collapse
Affiliation(s)
- Bassel Akache
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada; (B.A.); (G.A.); (F.C.S.); (Y.J.); (R.D.); (B.A.H.); (L.D.); (V.C.); (L.K.)
| | - Gerard Agbayani
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada; (B.A.); (G.A.); (F.C.S.); (Y.J.); (R.D.); (B.A.H.); (L.D.); (V.C.); (L.K.)
| | - Felicity C. Stark
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada; (B.A.); (G.A.); (F.C.S.); (Y.J.); (R.D.); (B.A.H.); (L.D.); (V.C.); (L.K.)
| | - Yimei Jia
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada; (B.A.); (G.A.); (F.C.S.); (Y.J.); (R.D.); (B.A.H.); (L.D.); (V.C.); (L.K.)
| | - Renu Dudani
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada; (B.A.); (G.A.); (F.C.S.); (Y.J.); (R.D.); (B.A.H.); (L.D.); (V.C.); (L.K.)
| | - Blair A. Harrison
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada; (B.A.); (G.A.); (F.C.S.); (Y.J.); (R.D.); (B.A.H.); (L.D.); (V.C.); (L.K.)
| | - Lise Deschatelets
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada; (B.A.); (G.A.); (F.C.S.); (Y.J.); (R.D.); (B.A.H.); (L.D.); (V.C.); (L.K.)
| | - Vandana Chandan
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada; (B.A.); (G.A.); (F.C.S.); (Y.J.); (R.D.); (B.A.H.); (L.D.); (V.C.); (L.K.)
| | - Edmond Lam
- Aquatic and Crop Resource Development, National Research Council Canada, Montreal, QC H4P 2R2, Canada; (E.L.); (U.D.H.); (S.R.)
| | - Usha D. Hemraz
- Aquatic and Crop Resource Development, National Research Council Canada, Montreal, QC H4P 2R2, Canada; (E.L.); (U.D.H.); (S.R.)
| | - Sophie Régnier
- Aquatic and Crop Resource Development, National Research Council Canada, Montreal, QC H4P 2R2, Canada; (E.L.); (U.D.H.); (S.R.)
| | - Lakshmi Krishnan
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada; (B.A.); (G.A.); (F.C.S.); (Y.J.); (R.D.); (B.A.H.); (L.D.); (V.C.); (L.K.)
| | - Michael J. McCluskie
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada; (B.A.); (G.A.); (F.C.S.); (Y.J.); (R.D.); (B.A.H.); (L.D.); (V.C.); (L.K.)
- Correspondence: ; Tel.: +1-613-993-9774
| |
Collapse
|
15
|
Jia Y, Akache B, Agbayani G, Chandan V, Dudani R, Harrison BA, Deschatelets L, Hemraz UD, Lam E, Régnier S, Stark FC, Krishnan L, McCluskie MJ. The Synergistic Effects of Sulfated Lactosyl Archaeol Archaeosomes When Combined with Different Adjuvants in a Murine Model. Pharmaceutics 2021; 13:pharmaceutics13020205. [PMID: 33540932 PMCID: PMC7913188 DOI: 10.3390/pharmaceutics13020205] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2021] [Revised: 01/27/2021] [Accepted: 01/28/2021] [Indexed: 12/14/2022] Open
Abstract
Archaeosomes, composed of sulfated lactosyl archaeol (SLA) glycolipids, have been proven to be an effective vaccine adjuvant in multiple preclinical models of infectious disease or cancer. SLA archaeosomes are a promising adjuvant candidate due to their ability to strongly stimulate both humoral and cytotoxic immune responses when simply admixed with an antigen. In the present study, we evaluated whether the adjuvant effects of SLA archaeosomes could be further enhanced when combined with other adjuvants. SLA archaeosomes were co-administered with five different Toll-like Receptor (TLR) agonists or the saponin QS-21 using ovalbumin as a model antigen in mice. Both humoral and cellular immune responses were greatly enhanced compared to either adjuvant alone when SLA archaeosomes were combined with either the TLR3 agonist poly(I:C) or the TLR9 agonist CpG. These results were also confirmed in a separate study using Hepatitis B surface antigen (HBsAg) and support the further evaluation of these adjuvant combinations.
Collapse
Affiliation(s)
- Yimei Jia
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada; (Y.J.); (B.A.); (G.A.); (V.C.); (R.D.); (B.A.H.); (L.D.); (F.C.S.); (L.K.)
| | - Bassel Akache
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada; (Y.J.); (B.A.); (G.A.); (V.C.); (R.D.); (B.A.H.); (L.D.); (F.C.S.); (L.K.)
| | - Gerard Agbayani
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada; (Y.J.); (B.A.); (G.A.); (V.C.); (R.D.); (B.A.H.); (L.D.); (F.C.S.); (L.K.)
| | - Vandana Chandan
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada; (Y.J.); (B.A.); (G.A.); (V.C.); (R.D.); (B.A.H.); (L.D.); (F.C.S.); (L.K.)
| | - Renu Dudani
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada; (Y.J.); (B.A.); (G.A.); (V.C.); (R.D.); (B.A.H.); (L.D.); (F.C.S.); (L.K.)
| | - Blair A. Harrison
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada; (Y.J.); (B.A.); (G.A.); (V.C.); (R.D.); (B.A.H.); (L.D.); (F.C.S.); (L.K.)
| | - Lise Deschatelets
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada; (Y.J.); (B.A.); (G.A.); (V.C.); (R.D.); (B.A.H.); (L.D.); (F.C.S.); (L.K.)
| | - Usha D. Hemraz
- Aquatic and Crop Resource Development, National Research Council Canada, Montreal, QC H4P 2R2, Canada; (U.D.H.); (E.L.); (S.R.)
| | - Edmond Lam
- Aquatic and Crop Resource Development, National Research Council Canada, Montreal, QC H4P 2R2, Canada; (U.D.H.); (E.L.); (S.R.)
| | - Sophie Régnier
- Aquatic and Crop Resource Development, National Research Council Canada, Montreal, QC H4P 2R2, Canada; (U.D.H.); (E.L.); (S.R.)
| | - Felicity C. Stark
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada; (Y.J.); (B.A.); (G.A.); (V.C.); (R.D.); (B.A.H.); (L.D.); (F.C.S.); (L.K.)
| | - Lakshmi Krishnan
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada; (Y.J.); (B.A.); (G.A.); (V.C.); (R.D.); (B.A.H.); (L.D.); (F.C.S.); (L.K.)
| | - Michael J. McCluskie
- Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada; (Y.J.); (B.A.); (G.A.); (V.C.); (R.D.); (B.A.H.); (L.D.); (F.C.S.); (L.K.)
- Correspondence: ; Tel.: +1-613-993-9774
| |
Collapse
|
16
|
Hu X, Zhao Y, Yang Y, Gong W, Sun X, Yang L, Zhang Q, Jin M. Akkermansia muciniphila Improves Host Defense Against Influenza Virus Infection. Front Microbiol 2021; 11:586476. [PMID: 33603716 PMCID: PMC7884316 DOI: 10.3389/fmicb.2020.586476] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2020] [Accepted: 12/21/2020] [Indexed: 12/24/2022] Open
Abstract
Influenza virus infection can alter the composition of the gut microbiota, while its pathogenicity can, in turn, be highly influenced by the gut microbiota. However, the details underlying these associations remain to be determined. The H7N9 influenza virus is an emerging zoonotic pathogen which has caused the death of 616 humans and has incurred huge losses in the poultry industry. Here, we investigated the effects of infection with highly pathogenic H7N9 on gut microbiota and determined potential anti-influenza microbes. 16S rRNA sequencing results show that H7N9 infection alters the mouse gut microbiota by promoting the growth of Akkermansia, Ruminococcus 1, and Ruminococcaceae UCG-010, and reducing the abundance of Rikenellaceae RC9 gut group and Lachnoclostridium. Although the abundance of Akkermansia muciniphila is positively related to H7N9 infection, the oral administration of cultures, especially of pasteurized A. muciniphila, can significantly reduce weight loss and mortality caused by H7N9 infection in mice. Furthermore, oral administration of live or pasteurized A. muciniphila significantly reduces pulmonary viral titers and the levels IL-1β and IL-6 but enhances the levels of IFN-β, IFN-γ, and IL-10 in H7N9-infected mice, suggesting that the anti-influenza role of A. muciniphila is due to its anti-inflammatory and immunoregulatory properties. Taken together, we showed that the changes in the gut microbiota are associated with H7N9 infection and demonstrated the anti-influenza role of A. muciniphila, which enriches current knowledge about how specific gut bacterial strains protect against influenza infection and suggests a potential anti-influenza probiotic.
Collapse
Affiliation(s)
- Xiaotong Hu
- Unit of Animal Infectious Diseases, State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China
| | - Ya Zhao
- Unit of Animal Infectious Diseases, State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China
| | - Yong Yang
- Unit of Animal Infectious Diseases, State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China
| | - Wenxiao Gong
- Unit of Animal Infectious Diseases, State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China
| | - Xiaomei Sun
- Unit of Animal Infectious Diseases, State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China
| | - Li Yang
- Unit of Animal Infectious Diseases, State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China
| | - Qiang Zhang
- Unit of Animal Infectious Diseases, State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China.,College of Biomedicine and Health, Huazhong Agricultural University, Wuhan, China
| | - Meilin Jin
- Unit of Animal Infectious Diseases, State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China.,Key Laboratory of Preventive Veterinary Medicine in Hubei Province, The Cooperative Innovation Center for Sustainable Pig Production, Wuhan, China.,Key Laboratory of Development of Veterinary Diagnostic Products, Ministry of Agriculture, Wuhan, China
| |
Collapse
|
17
|
Shin JH, Pawlowski SW, Warren CA. Teaching old mice new tricks: the utility of aged mouse models of C. difficile infection to study pathogenesis and rejuvenate immune response. Gut Microbes 2021; 13:1966255. [PMID: 34432545 PMCID: PMC8405153 DOI: 10.1080/19490976.2021.1966255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/14/2021] [Revised: 07/21/2021] [Accepted: 07/29/2021] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND Clostridioides difficile is a serious problem for the aging population. Aged mouse model of C. difficile infection (CDI) has emerged as a valuable tool to evaluate the mechanism of aging in CDI. METHODS We reviewed five published studies utilizing aged mice (7-28 months) for CDI model for findings that may advance our understanding of how aging influences outcome from CDI. RESULTS Aged mouse models of CDI uniformly demonstrated more severe disease in the old compared to young mice. Diminished neutrophil recruitment to intestinal tissue in aged mice is the most consistent finding. Differences in innate and humoral immune responses were also observed. The effects of aging on the outcome of infection were reversed by pharmacologic or microbiota-targeted interventions. CONCLUSION The aged mouse presents an important in vivo model to study CDI and elucidate the mechanisms underlying advanced age as an important risk factor for severe disease.
Collapse
Affiliation(s)
- Jae Hyun Shin
- Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA
| | | | - Cirle A. Warren
- Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA
| |
Collapse
|
18
|
Perera DJ, Hassan AS, Jia Y, Ricciardi A, McCluskie MJ, Weeratna RD, Ndao M. Adjuvanted Schistosoma mansoni-Cathepsin B With Sulfated Lactosyl Archaeol Archaeosomes or AddaVax™ Provides Protection in a Pre-Clinical Schistosomiasis Model. Front Immunol 2020; 11:605288. [PMID: 33304354 PMCID: PMC7701121 DOI: 10.3389/fimmu.2020.605288] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2020] [Accepted: 10/20/2020] [Indexed: 12/15/2022] Open
Abstract
Schistosomiasis threatens 800 million people worldwide. Chronic pathology manifests as hepatosplenomegaly, and intestinal schistosomiasis caused by Schistosoma mansoni can lead to liver fibrosis, cirrhosis, and blood in the stool. To assist the only FDA-approved drug, praziquantel, in parasite elimination, the development of a vaccine would be of high value. S. mansoni Cathepsin B (SmCB) is a well-documented vaccine target for intestinal schistosomiasis. Herein, we test the increased efficacy and immunogenicity of SmCB when combined with sulfated lactosyl archaeol (SLA) archaeosomes or AddaVax™ (a squalene based oil-in-water emulsion). Both vaccine formulations resulted in robust humoral and cell mediated immune responses. Impressively, both formulations were able to reduce parasite burden greater than 40% (WHO standard), with AddaVax™ reaching 86.8%. Additionally, SmCB with both adjuvants were able to reduce granuloma size and the amount of larval parasite hatched from feces, which would reduce transmission. Our data support SmCB as a target for S. mansoni vaccination; especially when used in an adjuvanted formulation.
Collapse
Affiliation(s)
- Dilhan J Perera
- Division of Experimental Medicine, Department of Medicine, McGill University, Montreal, QC, Canada.,Infectious Diseases and Immunity in Global Health Program, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada
| | - Adam S Hassan
- Infectious Diseases and Immunity in Global Health Program, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada.,Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada
| | - Yimei Jia
- Human Health Therapeutics Research Centre, National Research Council Canada, Ottawa, ON, Canada
| | - Alessandra Ricciardi
- Infectious Diseases and Immunity in Global Health Program, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada.,Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada
| | - Michael J McCluskie
- Human Health Therapeutics Research Centre, National Research Council Canada, Ottawa, ON, Canada
| | - Risini D Weeratna
- Human Health Therapeutics Research Centre, National Research Council Canada, Ottawa, ON, Canada
| | - Momar Ndao
- Division of Experimental Medicine, Department of Medicine, McGill University, Montreal, QC, Canada.,Infectious Diseases and Immunity in Global Health Program, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada.,Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada.,National Reference Center for Parasitology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
| |
Collapse
|
19
|
Agbayani G, Jia Y, Akache B, Chandan V, Iqbal U, Stark FC, Deschatelets L, Lam E, Hemraz UD, Régnier S, Krishnan L, McCluskie MJ. Mechanistic insight into the induction of cellular immune responses by encapsulated and admixed archaeosome-based vaccine formulations. Hum Vaccin Immunother 2020; 16:2183-2195. [PMID: 32755430 PMCID: PMC7553676 DOI: 10.1080/21645515.2020.1788300] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Archaeosomes are liposomes formulated using total polar lipids (TPLs) or semi-synthetic glycolipids derived from archaea. Conventional archaeosomes with entrapped antigen exhibit robust adjuvant activity as demonstrated by increased antigen-specific humoral and cell-mediated responses and enhanced protective immunity in various murine infection and cancer models. However, antigen entrapment efficiency can vary greatly resulting in antigen loss during formulation and variable antigen:lipid ratios. In order to circumvent this, we recently developed an admixed archaeosome formulation composed of a single semi-synthetic archaeal lipid (SLA, sulfated lactosylarchaeol) which can induce similarly robust adjuvant activity as an encapsulated formulation. Herein, we evaluate and compare the mechanisms involved in the induction of early innate and antigen-specific responses by both admixed (Adm) and encapsulated (Enc) SLA archaeosomes. We demonstrate that both archaeosome formulations result in increased immune cell infiltration, enhanced antigen retention at injection site and increased antigen uptake by antigen-presenting cells and other immune cell types, including neutrophils and monocytes following intramuscular injection to mice using ovalbumin as a model antigen. In vitro studies demonstrate SLA in either formulation is preferentially taken up by macrophages. Although the encapsulated formulation was better able to induce antigen-specific CD8+ T cell activation by dendritic cells in vitro, both encapsulated and admixed formulations gave equivalently enhanced protection from tumor challenge when tested in vivo using a B16-OVA melanoma model. Despite some differences in the immunostimulatory profile relative to the SLA (Enc) formulation, SLA (Adm) induces strong in vivo immunogenicity and efficacy, while offering an ease of formulation.
Collapse
Affiliation(s)
- Gerard Agbayani
- Human Health Therapeutics, National Research Council Canada , Ottawa, ON, Canada
| | - Yimei Jia
- Human Health Therapeutics, National Research Council Canada , Ottawa, ON, Canada
| | - Bassel Akache
- Human Health Therapeutics, National Research Council Canada , Ottawa, ON, Canada
| | - Vandana Chandan
- Human Health Therapeutics, National Research Council Canada , Ottawa, ON, Canada
| | - Umar Iqbal
- Human Health Therapeutics, National Research Council Canada , Ottawa, ON, Canada
| | - Felicity C Stark
- Human Health Therapeutics, National Research Council Canada , Ottawa, ON, Canada
| | - Lise Deschatelets
- Human Health Therapeutics, National Research Council Canada , Ottawa, ON, Canada
| | - Edmond Lam
- Aquatic and Crop Resource Development, National Research Council Canada , Montreal, QC, Canada
| | - Usha D Hemraz
- Aquatic and Crop Resource Development, National Research Council Canada , Montreal, QC, Canada
| | - Sophie Régnier
- Aquatic and Crop Resource Development, National Research Council Canada , Montreal, QC, Canada
| | - Lakshmi Krishnan
- Human Health Therapeutics, National Research Council Canada , Ottawa, ON, Canada
| | - Michael J McCluskie
- Human Health Therapeutics, National Research Council Canada , Ottawa, ON, Canada
| |
Collapse
|
20
|
Jia Y, Chandan V, Akache B, Qian H, Jakubek ZJ, Vinogradov E, Dudani R, Harrison BA, Jamshidi MP, Stark FC, Deschatelets L, Sauvageau J, Williams D, Krishnan L, McCluskie MJ. Assessment of stability of sulphated lactosyl archaeol archaeosomes for use as a vaccine adjuvant. J Liposome Res 2020; 31:237-245. [PMID: 32583693 DOI: 10.1080/08982104.2020.1786115] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Archaeosomes, composed of sulphated lactosyl archaeol (SLA) glycolipids, have been proven to be an effective vaccine adjuvant in multiple preclinical models of infectious disease or cancer. In addition to efficacy, the stability of vaccine components including the adjuvant is an important parameter to consider when developing novel vaccine formulations. To properly evaluate the potential of SLA glycolipids to be used as vaccine adjuvants in a clinical setting, a comprehensive evaluation of their stability is required. Herein, we evaluated the long term stability of preformed empty SLA archaeosomes prior to admixing with antigen at 4 °C or 37 °C for up to 6 months. In addition, the stability of adjuvant and antigen was evaluated for up to 1 month following admixing. Multiple analytical parameters evaluating the molecular integrity of SLA and the liposomal profile were assessed. Following incubation at 4 °C or 37 °C, the SLA glycolipid did not show any pattern of degradation as determined by mass spectroscopy, nuclear magnetic resonance (NMR) and thin layer chromatography (TLC). In addition, SLA archaeosome vesicle characteristics, such as size, zeta potential, membrane fluidity and vesicular morphology, were largely consistent throughout the course of the study. Importantly, following storage for 6 months at both 4 °C and 37 °C, the adjuvant properties of empty SLA archaeosomes were unchanged, and following admixing with antigen, the immunogenicity of the vaccine formulations was also unchanged when stored at both 4 °C and 37 °C for up to 1 month. Overall this indicates that SLA archaeosomes are highly stable adjuvants that retain their activity over an extended period of time even when stored at high temperatures.
Collapse
Affiliation(s)
- Yimei Jia
- Human Health Therapeutics Research Center, National Research Council Canada, Ottawa, ON, Canada
| | - Vandana Chandan
- Human Health Therapeutics Research Center, National Research Council Canada, Ottawa, ON, Canada
| | - Bassel Akache
- Human Health Therapeutics Research Center, National Research Council Canada, Ottawa, ON, Canada
| | - Hui Qian
- Nanotechnology Research Center, National Research Council Canada, Edmonton, AB, Canada
| | - Zygmunt J Jakubek
- Metrology Research Center, National Research Council Canada, Ottawa, ON, Canada
| | - Evguenii Vinogradov
- Human Health Therapeutics Research Center, National Research Council Canada, Ottawa, ON, Canada
| | - Renu Dudani
- Human Health Therapeutics Research Center, National Research Council Canada, Ottawa, ON, Canada
| | - Blair A Harrison
- Human Health Therapeutics Research Center, National Research Council Canada, Ottawa, ON, Canada
| | - Mohammad P Jamshidi
- Human Health Therapeutics Research Center, National Research Council Canada, Ottawa, ON, Canada
| | - Felicity C Stark
- Human Health Therapeutics Research Center, National Research Council Canada, Ottawa, ON, Canada
| | - Lise Deschatelets
- Human Health Therapeutics Research Center, National Research Council Canada, Ottawa, ON, Canada
| | - Janelle Sauvageau
- Human Health Therapeutics Research Center, National Research Council Canada, Ottawa, ON, Canada
| | - Dean Williams
- Human Health Therapeutics Research Center, National Research Council Canada, Ottawa, ON, Canada
| | - Lakshmi Krishnan
- Human Health Therapeutics Research Center, National Research Council Canada, Ottawa, ON, Canada
| | - Michael J McCluskie
- Human Health Therapeutics Research Center, National Research Council Canada, Ottawa, ON, Canada
| |
Collapse
|
21
|
Akache B, Deschatelets L, Harrison BA, Dudani R, Stark FC, Jia Y, Landi A, Law JLM, Logan M, Hockman D, Kundu J, Tyrrell DL, Krishnan L, Houghton M, McCluskie MJ. Effect of Different Adjuvants on the Longevity and Strength of Humoral and Cellular Immune Responses to the HCV Envelope Glycoproteins. Vaccines (Basel) 2019; 7:vaccines7040204. [PMID: 31816920 PMCID: PMC6963754 DOI: 10.3390/vaccines7040204] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2019] [Revised: 11/28/2019] [Accepted: 11/30/2019] [Indexed: 12/24/2022] Open
Abstract
Infection by Hepatitis C virus (HCV) can lead to liver cirrhosis/hepatocellular carcinoma and remains a major cause of serious disease morbidity and mortality worldwide. However, current treatment regimens remain inaccessible to most patients, particularly in developing countries, and, therefore, the development of a novel vaccine capable of protecting subjects from chronic infection by HCV could greatly reduce the rates of HCV infection, subsequent liver pathogenesis, and in some cases death. Herein, we evaluated two different semi-synthetic archaeosome formulations as an adjuvant to the E1/E2 HCV envelope protein in a murine model and compared antigen-specific humoral (levels of anti-E1/E2 IgG and HCV pseudoparticle neutralization) and cellular responses (numbers of antigen-specific cytokine-producing T cells) to those generated with adjuvant formulations composed of mimetics of commercial adjuvants including a squalene oil-in-water emulsion, aluminum hydroxide/monophosphoryl lipid A (MPLA) and liposome/MPLA/QS-21. In addition, we measured the longevity of these responses, tracking humoral, and cellular responses up to 6 months following vaccination. Overall, we show that the strength and longevity of anti-HCV responses can be influenced by adjuvant selection. In particular, a simple admixed sulfated S-lactosylarchaeol (SLA) archaeosome formulation generated strong levels of HCV neutralizing antibodies and polyfunctional antigen-specific CD4 T cells producing multiple cytokines such as IFN-γ, TNF-α, and IL-2. While liposome/MPLA/QS-21 as adjuvant generated superior cellular responses, the SLA E1/E2 admixed formulation was superior or equivalent to the other tested formulations in all immune parameters tested.
Collapse
Affiliation(s)
- Bassel Akache
- National Research Council Canada, Human Health Therapeutics, 1200 Montreal Rd, Ottawa, ON K1T 0H1, Canada; (B.A.); (L.D.); (B.A.H.); (R.D.); (F.C.S.); (Y.J.); (L.K.)
| | - Lise Deschatelets
- National Research Council Canada, Human Health Therapeutics, 1200 Montreal Rd, Ottawa, ON K1T 0H1, Canada; (B.A.); (L.D.); (B.A.H.); (R.D.); (F.C.S.); (Y.J.); (L.K.)
| | - Blair A. Harrison
- National Research Council Canada, Human Health Therapeutics, 1200 Montreal Rd, Ottawa, ON K1T 0H1, Canada; (B.A.); (L.D.); (B.A.H.); (R.D.); (F.C.S.); (Y.J.); (L.K.)
| | - Renu Dudani
- National Research Council Canada, Human Health Therapeutics, 1200 Montreal Rd, Ottawa, ON K1T 0H1, Canada; (B.A.); (L.D.); (B.A.H.); (R.D.); (F.C.S.); (Y.J.); (L.K.)
| | - Felicity C. Stark
- National Research Council Canada, Human Health Therapeutics, 1200 Montreal Rd, Ottawa, ON K1T 0H1, Canada; (B.A.); (L.D.); (B.A.H.); (R.D.); (F.C.S.); (Y.J.); (L.K.)
| | - Yimei Jia
- National Research Council Canada, Human Health Therapeutics, 1200 Montreal Rd, Ottawa, ON K1T 0H1, Canada; (B.A.); (L.D.); (B.A.H.); (R.D.); (F.C.S.); (Y.J.); (L.K.)
| | - Amir Landi
- Li Ka Shing Institute of Virology, Department of Medical Microbiology & Immunology, University of Alberta, 6-010 Katz Group-Rexall Centre for Health Research, Edmonton, AB T6G 2E1, Canada; (A.L.); (J.L.M.L.); (M.L.); (D.H.); (J.K.); (D.L.T.); (M.H.)
| | - John L. M. Law
- Li Ka Shing Institute of Virology, Department of Medical Microbiology & Immunology, University of Alberta, 6-010 Katz Group-Rexall Centre for Health Research, Edmonton, AB T6G 2E1, Canada; (A.L.); (J.L.M.L.); (M.L.); (D.H.); (J.K.); (D.L.T.); (M.H.)
| | - Michael Logan
- Li Ka Shing Institute of Virology, Department of Medical Microbiology & Immunology, University of Alberta, 6-010 Katz Group-Rexall Centre for Health Research, Edmonton, AB T6G 2E1, Canada; (A.L.); (J.L.M.L.); (M.L.); (D.H.); (J.K.); (D.L.T.); (M.H.)
| | - Darren Hockman
- Li Ka Shing Institute of Virology, Department of Medical Microbiology & Immunology, University of Alberta, 6-010 Katz Group-Rexall Centre for Health Research, Edmonton, AB T6G 2E1, Canada; (A.L.); (J.L.M.L.); (M.L.); (D.H.); (J.K.); (D.L.T.); (M.H.)
| | - Juthika Kundu
- Li Ka Shing Institute of Virology, Department of Medical Microbiology & Immunology, University of Alberta, 6-010 Katz Group-Rexall Centre for Health Research, Edmonton, AB T6G 2E1, Canada; (A.L.); (J.L.M.L.); (M.L.); (D.H.); (J.K.); (D.L.T.); (M.H.)
| | - D. Lorne Tyrrell
- Li Ka Shing Institute of Virology, Department of Medical Microbiology & Immunology, University of Alberta, 6-010 Katz Group-Rexall Centre for Health Research, Edmonton, AB T6G 2E1, Canada; (A.L.); (J.L.M.L.); (M.L.); (D.H.); (J.K.); (D.L.T.); (M.H.)
| | - Lakshmi Krishnan
- National Research Council Canada, Human Health Therapeutics, 1200 Montreal Rd, Ottawa, ON K1T 0H1, Canada; (B.A.); (L.D.); (B.A.H.); (R.D.); (F.C.S.); (Y.J.); (L.K.)
| | - Michael Houghton
- Li Ka Shing Institute of Virology, Department of Medical Microbiology & Immunology, University of Alberta, 6-010 Katz Group-Rexall Centre for Health Research, Edmonton, AB T6G 2E1, Canada; (A.L.); (J.L.M.L.); (M.L.); (D.H.); (J.K.); (D.L.T.); (M.H.)
| | - Michael J. McCluskie
- National Research Council Canada, Human Health Therapeutics, 1200 Montreal Rd, Ottawa, ON K1T 0H1, Canada; (B.A.); (L.D.); (B.A.H.); (R.D.); (F.C.S.); (Y.J.); (L.K.)
- Correspondence:
| |
Collapse
|
22
|
Simplified Admix Archaeal Glycolipid Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Enhances Protection from Murine Melanoma. Biomedicines 2019; 7:biomedicines7040091. [PMID: 31771150 PMCID: PMC6966619 DOI: 10.3390/biomedicines7040091] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2019] [Revised: 11/06/2019] [Accepted: 11/13/2019] [Indexed: 01/13/2023] Open
Abstract
Archaeosomes are liposomes composed of natural or synthetic archaeal lipids that when used as adjuvants induce strong long-lasting humoral and cell-mediated immune responses against entrapped antigens. However, traditional entrapped archaeosome formulations have only low entrapment efficiency, therefore we have developed a novel admixed formulation which offers many advantages, including reduced loss of antigen, consistency of batch-to-batch production as well as providing the option to formulate the vaccine immediately before use, which is beneficial for next generation cancer therapy platforms that include patient specific neo-antigens or for use with antigens that are less stable. Herein, we demonstrate that, when used in combination with anti-CTLA-4 and anti-PD-1 checkpoint therapy, this novel admixed archaeosome formulation, comprised of preformed sulfated lactosyl archaeol (SLA) archaeosomes admixed with OVA antigen (SLA–OVA (adm)), was as effective at inducing strong CD8+ T cell responses and protection from a B16-OVA melanoma tumor challenge as the traditionally formulated archaeosomes with encapsulated OVA protein. Furthermore, archaeosome vaccine formulations combined with anti-CTLA-4 and anti-PD-1 therapy, induced OVA-CD8+ T cells within the tumor and immunohistochemical analysis revealed the presence of CD8+ T cells associated with dying or dead tumor cells as well as within or around tumor blood vessels. Overall, archaeosomes constitute an attractive option for use with combinatorial checkpoint inhibitor cancer therapy platforms.
Collapse
|
23
|
Haq K, Jia Y, Elahi SM, MacLean S, Akache B, Gurnani K, Chattopadhyay A, Nazemi-Moghaddam N, Gilbert R, McCluskie MJ, Weeratna RD. Evaluation of recombinant adenovirus vectors and adjuvanted protein as a heterologous prime-boost strategy using HER2 as a model antigen. Vaccine 2019; 37:7029-7040. [DOI: 10.1016/j.vaccine.2019.08.079] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2019] [Revised: 08/23/2019] [Accepted: 08/29/2019] [Indexed: 12/27/2022]
|
24
|
Kamen AA, Lua LHL, Mukhopadhyay TK. Vaccine Technology VII: Beyond the "decade of vaccines". Vaccine 2019; 37:6931-6932. [PMID: 31623914 DOI: 10.1016/j.vaccine.2019.09.083] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- Amine A Kamen
- Department of Bioengineering, McGill University, Montreal, Canada.
| | - Linda H L Lua
- Protein Expression Facility, The University of Queensland, Brisbane, Australia.
| | | |
Collapse
|